文献速递胸部肿瘤头颈与中枢神经肿瘤

阿来替尼对比克唑替尼一线治疗ALK阳性晚期非小细胞肺癌:ALEX III期研究最终总生存分析

Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.
PubMed 文献 · Ann Oncol · 2025-10-17

ALEX III期随机试验对303例初治ALK阳性晚期NSCLC患者比较阿来替尼与克唑替尼,最终分析显示阿来替尼中位总生存81.1个月对比克唑替尼54.2个月(HR 0.78),中位缓解持续时间42.3个月对比11.1个月(HR 0.41),长期安全性无新发问题。

要点

  • 阿来替尼一线治疗ALK阳性晚期NSCLC中位OS达81.1个月,克唑替尼为54.2个月(HR 0.78)。
  • 基线有CNS转移者中位OS阿来替尼63.4个月对比克唑替尼30.9个月(HR 0.68)。
  • 确认缓解者中位DOR阿来替尼42.3个月显著优于克唑替尼11.1个月(HR 0.41)。

核心结论

  • 最终OS数据支持阿来替尼一线治疗ALK阳性NSCLC具有持久的长期全身及颅内疗效,确认其为该场景标准治疗。

研究设计与样本

  • ALEX为全球随机III期试验,入组303例初治III/IV期ALK阳性NSCLC患者,随机接受阿来替尼600mg每日两次或克唑替尼250mg每日两次治疗。
  • 主要终点为研究者评估的无进展生存期(既往已报告),关键次要终点包括总生存、缓解持续时间和安全性。

主要发现

  • 更新数据截止2025年4月28日,阿来替尼组中位随访53.5个月,克唑替尼组23.3个月,中位OS分别为81.1个月(95%CI 62.3个月-不可估计)和54.2个月(95%CI 34.6-75.6个月),HR 0.78(95%CI 0.56-1.08)。
  • 基线有CNS转移者中位OS阿来替尼63.4个月(n=59)对比克唑替尼30.9个月(n=53),HR 0.68(95%CI 0.40-1.15)。
  • 基线无CNS转移者中位OS阿来替尼94.0个月(n=93)对比克唑替尼69.8个月(n=98),HR 0.87(95%CI 0.58-1.32)。
  • 确认缓解者中位DOR阿来替尼42.3个月(95%CI 31.3-51.3个月)对比克唑替尼11.1个月(95%CI 7.9-13.0个月),HR 0.41(95%CI 0.30-0.56)。
  • 阿来替尼中位治疗时长28.1个月,长期安全性与既往报告一致,未发现新的或非预期安全性问题。

关键数值与推荐

  • 阿来替尼剂量为600mg每日两次,克唑替尼为250mg每日两次,均持续给药至疾病进展、不可接受毒性、退出或死亡。

临床怎么用

  • 支持阿来替尼作为ALK阳性晚期NSCLC初治患者的标准一线选择,尤其关注其长期生存及颅内疗效获益。

局限性

  • 总生存HR的95%CI上限跨越1,组间OS差异未达统计学显著。
  • 两组中位随访时间不均衡(阿来替尼53.5个月 vs 克唑替尼23.3个月)。
  • 基线CNS转移亚组样本量较小,OS改善的置信区间较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ALEX, a global, randomized, phase III trial evaluated alectinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer (NSCLC). This final analysis provides mature overall survival (OS), duration of response (DOR) and long-term safety data. PATIENTS AND METHODS: Treatment-naïve patients with stage III/IV ALK-positive NSCLC were randomly assigned to receive alectinib [600 mg twice daily (b.i.d.)] or crizotinib (250 mg b.i.d.) until disease progression, unacceptable toxicity, withdrawal, or death. Primary endpoint was investigator-assessed progression-free survival (previously reported). Key secondary endpoints included OS, DOR and safety. RESULTS: A total of 303 patients (alectinib, n = 152; crizotinib, n = 151) were enrolled. At the updated data cut-off (28 April 2025), after a median follow-up of 53.5 (alectinib) and 23.3 (crizotinib) months, median OS was 81.1 [95% confidence interval (CI) 62.3 months-not estimable] versus 54.2 (95% CI 34.6-75.6 months) months, respectively [hazard ratio (HR) 0.78; 95% CI 0.56-1.08]. Improvement in median OS was observed with alectinib in patients with and without central nervous system (CNS) metastases at baseline [with CNS metastases: 63.4 (n = 59) versus 30.9 (n = 53) months with alectinib versus crizotinib, respectively (HR 0.68; 95% CI 0.40-1.15); without CNS metastases: 94.0 (n = 93) versus 69.8 (n = 98) months (HR 0.87; 95% CI 0.58-1.32)]. Median DOR in confirmed responders was longer with alectinib (42.3 months, 95% CI 31.3-51.3 months) versus crizotinib [11.1 months, 95% CI 7.9-13.0 months (HR 0.41; 95% CI 0.30-0.56)]. Long-term safety (median duration of alectinib treatment, 28.1 months) remained consistent with earlier reports, with no new or unexpected safety concerns identified. CONCLUSIONS: These final OS data show the sustained long-term systemic and intracranial efficacy of alectinib in the first-line treatment of ALK-positive NSCLC and confirm alectinib as a standard of care in this setting.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Peters S, Camidge R, Dziadziuszko R, et al. Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study. Ann Oncol. 2025. PMID: 41110693. doi:10.1016/j.annonc.2025.09.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。